Appel, Camilla Kristine <br/><br/>
The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain.  [electronic resource] 

 -  Scientific reports  07 2017 
 - 4792 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2045-2322 
<br/><br/><label>Standard No.: </label>10.1038/s41598-017-05029-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Bone Neoplasms--complications<br/>Bone and Bones--drug effects<br/>Cell Line, Tumor<br/>Dasatinib--pharmacology<br/>Female<br/>Gene Expression Regulation, Neoplastic<br/>Genes, Reporter<br/>Luciferases--genetics<br/>Mammary Neoplasms, Animal--complications<br/>Osteoclasts--drug effects<br/>Osteosarcoma--complications<br/>Pain--drug therapy<br/>Pain Management--methods<br/>Pain Measurement--methods<br/>Phosphorylation--drug effects<br/>Protein Kinase Inhibitors--pharmacology<br/>Rats<br/>Rats, Sprague-Dawley<br/>Receptors, N-Methyl-D-Aspartate--genetics<br/>Signal Transduction<br/>Tartrate-Resistant Acid Phosphatase--antagonists & inhibitors<br/>src-Family Kinases--antagonists & inhibitors